Answers are grounded in this paper and cite their sources.
Dear Editor, Extramammary Paget disease (EMPD) is a rare cutaneous malignancy that mainly affects the genital area in the older population.1 In most EMPD cases, tumour cells are localized to the epidermis, and prognosis is relatively favourable.2 However, once tumour cells invade the dermis, patients are at a risk of developing lymph node and visceral metastases, and the prognosis becomes significantly poorer.3 4 To date, several studies, including one previously performed by our group,5 have described the efficacy of docetaxel (DTX) for the treatment of advanced EMPD. However, to our knowledge, no previous case series has described the efficacy of chemotherapy while also considering outcomes in the second‐line setting. Here, we describe the efficacy of first‐line DTX and describe outcomes for other chemotherapeutic regimens in the second‐line setting. This retrospective study included 25 patients with advanced EMPD, who received first‐line DTX at our institute from May 2008 to June 2018. Three patients were excluded as they had received prior chemotherapy at another institution. Thus, 22 patients (six female, 16 male) were included in the final analysis. The mean age of the patients was 73·6 years (range 54–86). Metastasis occurred in the lymph nodes in 19 patients, in the bone for four patients, in the lung for three patients and in the liver for four patients. DTX (60 mg m−2, every 3 weeks) was administered to all patients as first‐line therapy. Chemotherapeutic regimens beyond the first‐line setting were as follows: eight patients receiving weekly paclitaxel (PTX) (60 mg m−2, once per week), one patient receiving FECOM [5‐fluorouracil (5‐FU) 350 mg m−2, epirubicin 40 mg m−2, carboplatin 300 mg m−2, vincristine 0·7 mg m−2 + mitomycin C 3·5 mg m−2, every 4 weeks] and one patient receiving low‐dose 5‐FU combined with cisplatin (FP) (5‐FU 800 mg m−2 + cisplatin 15 mg m−2, every 4 weeks). Clinical data, including patient attributes, chemotherapeutic regimen, tumour response, adverse events (AEs), overall survival (OS) and progression‐free survival (PFS) were collected. Tumour response was defined according to the Response Evaluation Criteria in Solid Tumors 1·1. To evaluate tumour response and AEs, we performed computed tomography every 1–3 months and blood sampling at least once a week. Subgroup analyses were performed by categorizing patients into the following two groups: patients with visceral metastases (n = 8) and those with inoperable lymphatic spread only (n = 14). All statistical analyses were performed using BellCurve for Excel (Social Survey Research Information Co. Ltd., Tokyo, Japan). Tumour responses were examined using Fisher's exact test. OS and PFS curves were estimated using the Kaplan–Meier method. A value of P < 0·05 was considered statistically significant. This research was approved by the ethics committee of the Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital. Patient characteristics and the efficacy of chemotherapeutic regimens are summarized in Table 1. The response rate (RR) and disease control rate (DCR) in patients treated with DTX were 32% and 73%, respectively. The median estimated PFS and median estimated OS were 9·0 months [95% confidence interval (CI) 5·0–13·0] and 20·6 months (95% CI 19·6–21·7), respectively. The RR and DCR were worse in patients with visceral metastases than in those with inoperable lymphatic spread only [0% vs. 50% (P = 0·02) and 50% vs. 93% (P = 0·04), respectively]. After the first tumour progression, 10 patients switched to second‐line chemotherapy. Of these patients, eight patients received weekly PTX and tended to demonstrate better OS than patients receiving other treatments. Haematological toxicities were the most common AEs and were more frequently observed with DTX than with other regimens. However, all AEs were well managed with granulocyte‐colony stimulating factor injections, and no patients required a blood transfusion. The efficacy of chemotherapeutic regimens DTX, docetaxel; PTX, paclitaxel; FP, 5‐fluorouracil + cisplatin, FECOM; 5‐fluorouracil + epirubicin + carboplatin + vincristine + mitomycin C; RR, response rate; DCR, disease control rate; mPFS: median progression‐free survival; mOS, median overall survival. aStatistically significant. The efficacy of chemotherapeutic regimens DTX, docetaxel; PTX, paclitaxel; FP, 5‐fluorouracil + cisplatin, FECOM; 5‐fluorouracil + epirubicin + carboplatin + vincristine + mitomycin C; RR, response rate; DCR, disease control rate; mPFS: median progression‐free survival; mOS, median overall survival. aStatistically significant. Owing to the rarity of EMPD, no single chemotherapy has been proven to be the most effective for the treatment of advanced EMPD. Tokuda et al. reviewed previous reports and retrospectively examined 22 patients with advanced EMPD who received FP.6 In their study, RR, mPFS and mOS were 59%, 5·2 months and 12 months, respectively. However, their analysis did not consider the site of metastasis; therefore, it was difficult to eliminate possible bias. Oashi et al. described the efficacy of FECOM in the management of seven patients with advanced EMPD and concluded that FECOM was effective for treating lymphatic metastasis.7 However, more than 50% of the patients discontinued chemotherapy after the third course. Compared with previous studies, the RR in this study was relatively low, possibly because our study included numerous patients with visceral metastases. However, based on the longer survival in this study compared with the previous study that used FP, we conclude that DTX administration provided a survival benefit, particularly among patients with nodal metastases only. In our study population, the development of lymphatic metastases was commonly observed in invasive EMPD, and lymphatic invasion is strongly associated with distant metastasis and poor survival.8 Therefore, the control of lymphatic spread may be critical to improving survival in advanced EMPD. In conclusion, DTX is effective in patients with advanced EMPD. Moreover, second‐line PTX after DTX failure might improve survival. As both DTX and PTX can be administered at outpatient clinics, we recommend taxanes as the preferred primary treatment option for advanced EMPD, especially in older patients.
No takes yet. Share an insight, caveat, or question.
Kato et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: